Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Short Interest Up 330.5% in June

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) was the recipient of a large increase in short interest in the month of June. As of June 15th, there was short interest totaling 16,744 shares, an increase of 330.5% from the May 31st total of 3,889 shares. Approximately 9.8% of the shares of the stock are sold short. Based on an average trading volume of 2,088 shares, the days-to-cover ratio is presently 8.0 days.

Institutional Investors Weigh In On Amplify Weight Loss Drug & Treatment ETF

An institutional investor recently bought a new stake in Amplify Weight Loss Drug & Treatment ETF stock. Cravens & Co Advisors LLC bought a new stake in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm bought 15,023 shares of the company’s stock, valued at approximately $390,000. Cravens & Co Advisors LLC owned 10.02% of Amplify Weight Loss Drug & Treatment ETF as of its most recent SEC filing.

Amplify Weight Loss Drug & Treatment ETF Stock Up 1.7%

Shares of THNR traded up $0.42 during trading hours on Friday, hitting $25.36. 2,062 shares of the company were exchanged, compared to its average volume of 2,102. Amplify Weight Loss Drug & Treatment ETF has a fifty-two week low of $21.70 and a fifty-two week high of $27.28. The company has a market cap of $4.31 million, a price-to-earnings ratio of 24.31 and a beta of 0.40. The firm’s fifty day moving average is $24.50 and its 200 day moving average is $25.10.

Amplify Weight Loss Drug & Treatment ETF Company Profile

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.